Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

ADHD Medication Associated with Reduced Risk of Motor Vehicle Crashes

By The JAMA Network Journals | May 15, 2017

In a study of more than 2.3 million patients in the United States with attention-deficit/hyperactivity disorder (ADHD), rates of motor vehicle crashes (MVCs) were lower when they had received their medication, according to a new article published by JAMA Psychiatry.

About 1.25 million people worldwide die annually because of MVCs. ADHD is a prevalent neurodevelopmental disorder with symptoms that include poor sustained attention, impaired impulse control and hyperactivity. ADHD affects 5 percent to 7 percent of children and adolescent and for many people it persists into adulthood. Prior studies have suggested people with ADHD are more likely to experience MVCs. Pharmacotherapy is a first-line treatment for the condition and rates of ADHD medication prescribing have increased over the last decade in the United States and in other countries.

Zheng Chang, Ph.D., M.Sc., of the Karolinska Institutet, Stockholm, Sweden, and coauthors identified more than 2.3 million U.S. patients with ADHD between 2005 and 2014 from commercial health insurance claims and identified emergency department visits for MVCs. Analyses compared the risk of MVCs during months when patients received their medication with the risk of MVCs during months when they did not.

Among the more than 2.3 million patients with ADHD (average age 32.5), 83.9 percent (more than 1.9 million) received at least one prescription for ADHD medication during the follow-up. There were 11,224 patients (0.5 percent) who had at least one emergency department visit for an MVC.

Patients with ADHD had a higher risk of an MVC than a control group of people who didn’t have ADHD or ADHD medication use. The use of medication in patients with ADHD was associated with reduced risk for MVC in both male and female patients, according to the results.

“These findings call attention to a prevalent and preventable cause of mortality and morbidity among patients with ADHD. If replicated, our results should be considered along with other potential benefits and harms associated with ADHD medication use,” the article concludes.

Limitations of the study include that it cannot prove causality because it is an observational study. Medication use also was measured by monthly filled prescriptions. Also, the study used emergency department visits due to MVCs as its main outcome so some MVCs that did not require medical services (for example less severe crashes or some fatal ones) were not included in the study.

Related Articles Read More >

Verily secures new investment from Nvidia
How Lantern Med Digital is helping build the digital layer of Costa Rica’s medtech boom
Norstella launches Atlas, a biopharma agentic platform that can ‘train you’
How a Duke-led HPC method brought cell-scale cancer simulation to a single cloud node 
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE